Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

Abstract

Cholinesterase inhibitor treatment may offer continued therapeutic benefit for up to 2 years in patients with moderate AD. Although both drugs performed similarly on cognition and behaviour, rivastigmine may provide greater benefit in activities of daily living and global functioning.